All In Biotech

Drug Trial Radar · NCT06552520

To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis in Subjects

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

500

Actual

Start

Oct 8, 2024

Primary completion

Sep 11, 2025

Study completion Jul 18, 2026

Sponsor

Sponsor type
Industry
First posted
Aug 14, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled clinical trial with 500 participants. In this study, the safety evaluation used the common toxic reaction criteria of the National Cancer Institute to evaluate the adverse events of the drugs, and the effectiveness evaluation used the eczema area and severity score and the overall investigator score to confirm the efficacy.

Conditions

  • Atopic Dermatitis

Interventions

  • TQH2722 injectionDrug

    Humanized interleukin-4 receptor alpha (4Rα) monoclonal antibody

  • Placebo of TQH2722 injectionDrug

    Placebo without drug substance

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants who achieved EASI-75 (≥75% improvement from baseline) on the eczema Area and Severity score (EASI)Time frame: Baseline to 16 weeks after treatment
  2. Subjects with an Investigator's Overall Rating (IGA) score (5-scale) of 0 or 1 and ≥2 points decline from baselineTime frame: Baseline to 16 weeks after treatment

Locations

73 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • Tongling People's Hospital

    Tongling, Anhui, China

  • The Second Affiliated Hospital of Wannan Medical College

    Wuhu, Anhui, China

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital of the Chinese People's Liberation Army Army Medical University

    Chongqing, Chongqing Municipality, China

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Chongqing Three Gorges Medical College affiliated People's Hospital

    Chongqing, Chongqing Municipality, China

  • The Second Affiliated Hospital of Xiamen Medical College

    Xiamen, Fujian, China

  • Dermatology Hospital of Southern Medical UniversityDermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China

  • Liuzhou People's Hospital

    Liuzhou, Guangxi, China

  • Cangzhou Central Hospital

    Cangzhou, Hebei, China

  • The Affiliated Hospital of Chengde Medical College

    Chengde, Hebei, China

  • Heilongjiang Provincial Hospital

    Harbin, Heilongjiang, China

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • Qiqihar Hospital of Traditional Chinese Medicine

    Qiqihar, Heilongjiang, China

  • Anyang District Hospital, Puyang City

    Anyang, Henan, China

  • The Second Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

  • Nanyang city first People's Hospital

    Nanyang, Henan, China

  • Sanmenxia Central Hospital

    Sanmenxia, Henan, China

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Zhengzhou, Henan, China

  • Jingzhou Central Hospital

    Jingzhou, Hubei, China

  • Wuhan University People's Hospital

    Wuhan, Hubei, China

  • Yichang Central People's Hospital

    Yichang, Hubei, China

  • The Second Xiangya Hospital, Central South University

    Changsha, Hunan, China

  • Xiangya Third Hospital, Central South University

    Changsha, Hunan, China

  • The First Affiliated Hospital of University of South China

    Hengyang, Hunan, China

  • Hunan Medical University General Hospital

    Huaihua, Hunan, China

  • The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology

    Baotou, Inner Mongolia, China

  • Baotou Central Hospital

    Baotou, Inner Mongolia, China

  • Affiliated Hospital of Inner Mongolia Medical University

    Hohhot, Inner Mongolia, China

  • Changzhou First People's Hospital

    Changzhou, Jiangsu, China

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • Suzhou Municipal Hospital

    Suzhou, Jiangsu, China

  • Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

  • Yancheng First People's Hospital

    Yancheng, Jiangsu, China

  • Affiliated Hospital of Jiangsu University

    Zhenjiang, Jiangsu, China

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.